gut.bmj22h
IDDF2019-ABS-0194 The role of tocotrienols in the treatment of non-alcoholic steatohepatitis- a meta-analysis
Background Chronic liver diseases (CLD) represent a major public health problem, accounting for significant mortality of more than 1.75 million deaths are attributed to it. Among these, Non-alcoholic ...
gut.bmj10d
Long-term hepatitis B surface antigen response after finite treatment of ARC-520 or JNJ-3989
Background and aims RNA interference has been extensively explored in patients with chronic hepatitis B (CHB) infection. We aimed to characterise the long-term efficacy of small interfering RNA (siRNA ...
gut.bmj23h
Cyclosporin for refractory ulcerative colitis
Inflammatory Bowel Disease Clinic, Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA. Correspondence to: Dr W J Sandborn, Division of Gastroenterology and Hepatology, ...
gut.bmj11d
Identification of PRMT5 as a therapeutic target in cholangiocarcinoma
Background Cholangiocarcinoma (CCA) is a very difficult-to-treat cancer. Chemotherapies are little effective and response to immune checkpoint inhibitors is limited. Therefore, new therapeutic ...
gut.bmj16d
Sphincterotomy for biliary sphincter of Oddi disorder and idiopathic acute recurrent pancreatitis: the RESPOnD longitudinal cohort
Objective Sphincter of Oddi disorders (SOD) are contentious conditions in patients whose abdominal pain, idiopathic acute pancreatitis (iAP) might arise from pressurisation at the sphincter of Oddi.
gut.bmj12d
Microbiota-induced S100A11-RAGE axis underlies immune evasion in right-sided colon adenomas and is a therapeutic target to boost anti-PD1 efficacy
2 Key Laboratory of Human Microbiome and Chronic Diseases (Sun Yat-sen University), Ministry of Education, Guangzhou, China Background Tumourigenesis in right-sided and left-sided colons demonstrated ...
gut.bmj10d
Proton pump inhibitors and risk of colorectal cancer
Objective To determine whether proton pump inhibitors (PPIs) are associated with an increased risk of colorectal cancer, compared with histamine-2 receptor antagonists (H2RAs). Design The United ...
gut.bmj9d
Disrupted spermatogenesis in a metabolic syndrome model: the role of vitamin A metabolism in the gut–testis axis
Objective Effects of the diet-induced gut microbiota dysbiosis reach far beyond the gut. We aim to uncover the direct evidence involving the gut–testis axis in the aetiology of impaired ...
gut.bmj10d
Milk polar lipids reduce lipid cardiovascular risk factors in overweight postmenopausal women: towards a gut sphingomyelin-cholesterol interplay
3 Université Clermont Auvergne, INRA, UNH, Unité de Nutrition Humaine, CRNH Auvergne, 63000, Clermont-Ferrand, France 4 Université Clermont Auvergne, CNRS, SIGMA Clermont, Institut Pascal, 63000, ...
gut.bmj9d
Impairment of spermatogenesis and sperm motility by the high-fat diet-induced dysbiosis of gut microbes
Objective High-fat diet (HFD)-induced metabolic disorders can lead to impaired sperm production. We aim to investigate if HFD-induced gut microbiota dysbiosis can functionally influence ...
gut.bmj5d
Intestinal ganglioneuromatosis and multiple endocrine neoplasia type 2B: implications for treatment
Dr V V Smith, Histopathology, Camelia Botnar Laboratories, Great Ormond Street Hospital, Great Ormond Street, London WC1N 3JH, UK. Three infants, who presented with intestinal obstruction due to ...
gut.bmj12d
Update on lactose malabsorption and intolerance: pathogenesis, diagnosis and clinical management
Correspondence to Dr Mark R Fox, Laboratory and Clinic for Disorders of Gastrointestinal Motility and Function, Center for Integrative Gastroenterology, Klinik Arlesheim, Arlesheim 4144, Switzerland; ...